 |
|
Effect of Fenofibrate Medication on Renal Function
Sungjong Kim, Kyungjin Ko, Sookyoung Park, Dong Ryul Lee, Jungun Lee
Korean J Fam Med. 2017;38(4):192-198. Published online 2017 Jul 20 DOI: https://doi.org/10.4082/kjfm.2017.38.4.192
|
|
Citations to this article as recorded by
 Icariside II prevents kidney fibrosis development in chronic kidney disease by promoting fatty acid oxidation
Meng Wang, Jing Wang, Lingchen Wang, Xiaoxuan Feng, Yiling Qian, Chaoyang Ye, Chen Wang
Phytotherapy Research.2024; 38(2): 839. CrossRef Shen-Shuai-II-Recipe inhibits tubular inflammation by PPARα-mediated fatty acid oxidation to attenuate fibroblast activation in fibrotic kidneys
Meng Wang, Lingchen Wang, Liang Zhou, Yizeng Xu, Chen Wang
Phytomedicine.2024; 126: 155450. CrossRef Frequency and predictors of inappropriate medication dosages for cardiovascular disease prevention in chronic kidney disease patients: A retrospective cross-sectional study in a Malaysian primary care clinic
Jazlan Jamaluddin, Mohamed-Syarif Mohamed-Yassin, Siti Nuradliah Jamil, Mohd Azzahi Mohamed Kamel, Mohamad Ya'akob Yusof
Heliyon.2023; 9(4): e14998. CrossRef Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial
Rene Rodriguez-Gutierrez, Jose Gerardo González, Deven Parmar, Farheen. Shaikh, Pio Cruz-López
Journal of Lipid Research.2022; 63(7): 100233. CrossRef PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
Simona Todisco, Anna Santarsiero, Paolo Convertini, Giulio De Stefano, Michele Gilio, Vito Iacobazzi, Vittoria Infantino
Biology.2022; 11(5): 792. CrossRef Three-dimensional electrochemical degradation of p-aminophenol with efficient honeycomb block AC@Ti-Cu-Ni-Zn-Sb-Mn particle electrodes
Jia Wan, Feiping Zhao, Yong Meng, Mengyan Guo, Chong-jian Tang, Yan Shi, Yong Ke, Rong Hu
Separation and Purification Technology.2021; 267: 118662. CrossRef Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy
Yohei Tomita, Deokho Lee, Kazuo Tsubota, Kazuno Negishi, Toshihide Kurihara
Journal of Clinical Medicine.2021; 10(20): 4666. CrossRef Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
Kazufumi Dohmen, Shin-ya Onohara, Shigeru Harada
The Korean Journal of Gastroenterology.2021; 78(4): 227. CrossRef Drug Therapies Affecting Renal Function: An Overview
Reem Y Alhassani, Reem M Bagadood, Rafal N Balubaid, Haneen I Barno, Mariah O Alahmadi, Nahla A Ayoub
Cureus.2021;[Epub] CrossRef Defective Mitochondrial Fatty Acid Oxidation and Lipotoxicity in Kidney Diseases
Hee-Seong Jang, Mi Ra Noh, Jinu Kim, Babu J. Padanilam
Frontiers in Medicine.2020;[Epub] CrossRef Fenofibrate-induced renal dysfunction, yes or no?
Fatemeh Emami, Amirali Hariri, Mohammad Matinfar, Mehdi Nematbakhsh
Journal of Research in Medical Sciences.2020; 25(1): 39. CrossRef PPARα Agonist Oral Therapy in Diabetic Retinopathy
Yohei Tomita, Deokho Lee, Kazuo Tsubota, Toshihide Kurihara
Biomedicines.2020; 8(10): 433. CrossRef Dyslipidemia in patients with chronic kidney disease: etiology and management
Magdaléna Dušejovská, Marek Vecka, Ivan Rychlík, Aleš Žák
Vnitřní lékařství.2020; 66(5): 275. CrossRef Lipid-lowering and antioxidative effects ofApium graveolensL. root flavonoid extracts
Yuan He, Yang Shi, Airong Zhang, Xiaoxia Zhang, Jing Sun, Li Tian
RSC Advances.2019; 9(46): 26757. CrossRef Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, Tan, Low, Marvalim, Lee, Tan
International Journal of Molecular Sciences.2019; 20(20): 5055. CrossRef
|